These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 3890393)
1. Is the antihypertensive effect of muzolimine due to volume depletion? Andreucci VE; Dal Canton A; Russo D; Veniero P; Oliva O; Cofelice E; Romano G Z Kardiol; 1985; 74 Suppl 2():43-7. PubMed ID: 3890393 [TBL] [Abstract][Full Text] [Related]
2. [Arterial hypertension in patients on chronic hemodialysis]. Zogović J; Mladenović Lj Srp Arh Celok Lek; 1996; 124(9-10):246-50. PubMed ID: 9102857 [TBL] [Abstract][Full Text] [Related]
3. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside]. Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983 [TBL] [Abstract][Full Text] [Related]
4. [Clinical and hemodynamic effects of medium-term treatment with muzolimine in subjects with essential arterial hypertension]. Licata G; Scaglione R; Parrinello G; Rini GB; Asta N G Ital Cardiol; 1986 Jul; 16(7):583-5. PubMed ID: 3781147 [TBL] [Abstract][Full Text] [Related]
5. Muzolimine in the treatment of essential arterial hypertension not controlled with other antihypertensive drugs. Beneitez C Z Kardiol; 1985; 74 Suppl 2():52-5. PubMed ID: 4002805 [TBL] [Abstract][Full Text] [Related]
6. Changes of electrolyte excretion, renin activity, angiotensin-II and aldosterone concentrations during administration of 3-amino-1-(3,4-dichloro-a-methyl-benzyl)-2-pyrazolin-5-one (Bay g 2821). Schnurr E; Küppers H Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):453-6. PubMed ID: 511420 [TBL] [Abstract][Full Text] [Related]
7. Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness. Schiffl H; Weidmann P; Beretta-Piccoli C; Cottier C; Seiler AJ; Ziegler WH Eur J Clin Pharmacol; 1982; 23(3):215-20. PubMed ID: 6756933 [TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin-aldosterone axis. Bernardi M; De Palma R; Trevisani F; Santini C; Servadei D; Gasbarrini G Z Kardiol; 1985; 74 Suppl 2():129-34. PubMed ID: 3890391 [TBL] [Abstract][Full Text] [Related]
9. Normokalemic hyperaldosteronism in patients with resistant hypertension. Benchetrit S; Bernheim J; Podjarny E Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302 [TBL] [Abstract][Full Text] [Related]
10. Circulatory volume in essential hypertension. Relationships with age, blood pressure, exchangeable sodium, renin, aldosterone and catecholamines. Beretta-Piccoli C; Weidmann P Miner Electrolyte Metab; 1984; 10(5):292-300. PubMed ID: 6387428 [TBL] [Abstract][Full Text] [Related]
11. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. Bauer IH; Reams GP; Wu Z; Lau-Sieckman A J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905 [TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine response to cardiac transplantation. Masters RG; Davies RA; Keon WJ; Walley VM; Koshal A; de Bold AJ Can J Cardiol; 1993 Sep; 9(7):609-17. PubMed ID: 8221359 [TBL] [Abstract][Full Text] [Related]
13. Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension. Muiesan G; Agabiti-Rosei E; Castellano M; Alicandri CL; Corea L; Fariello R; Beschi M; Romanelli G J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S325-9. PubMed ID: 6184562 [TBL] [Abstract][Full Text] [Related]
14. Treatment of mild to moderate essential hypertension with muzolimine. Two years of follow-up. Amabile G; Serradimigni A Z Kardiol; 1985; 74 Suppl 2():48-51. PubMed ID: 4002804 [TBL] [Abstract][Full Text] [Related]
15. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension. Man in't Veld AJ; Schalekamp MA Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800 [TBL] [Abstract][Full Text] [Related]
16. Calf muscle haemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with a familial predisposition to hypertension: changes during increased salt intake. Gudmundsson O; Andersson OK; Aurell M; Wikstrand JM; Berglund GL J Hypertens; 1984 Jun; 2(3):291-6. PubMed ID: 6397530 [TBL] [Abstract][Full Text] [Related]
17. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Jensen J; Henik RA; Brownfield M; Armstrong J Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564 [TBL] [Abstract][Full Text] [Related]
18. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?]. Horký K Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of muzolimine after acute and chronic dosing in hypertensive patients with mild renal insufficiency. Mann J; Ritter W; Heckmann N; Sörgel F; Ritz E Z Kardiol; 1985; 74 Suppl 2():77-9. PubMed ID: 4002808 [TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of muzolimine and indapamide during treatment for essential hypertension. Kirsten R; Molz KH; Tzonev I; Nelson K Z Kardiol; 1985; 74 Suppl 2():66-72. PubMed ID: 4002807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]